We recently reported that pharmacologic inhibition of SphK2 using ABC294640 induces dose-dependent, caspase-mediated apoptosis for KSHV-infected PEL cell lines and suppresses PEL tumor progression in vivo[18]. The gene discussed is SPHK2; the disease is primary effusion lymphoma.